NCT07209176 Physician- and Patient-based Barriers to NGS Testing
| NCT ID | NCT07209176 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
| Condition | Metastatic Prostate Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 256 participants |
| Start Date | 2026-01-06 |
| Primary Completion | 2027-09-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 256 participants in total. It began in 2026-01-06 with a primary completion date of 2027-09-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to improve next-generation sequencing (NGS) testing rates at Johns Hopkins in patients with metastatic prostate cancer. Investigators believe by targeting two barriers, provider-level and patient-level, will improve the testing rate of NGS at Johns Hopkins.
Eligibility Criteria
Inclusion Criteria: * men diagnosed with metastatic prostate cancer * seen by Johns Hopkins Medical Oncology as a new patient visit between January 1, 2025 and December 31, 2026 Exclusion Criteria: \- Patients who have already had NGS testing performed.
Contact & Investigator
Catherine Marshall, MD
PRINCIPAL INVESTIGATOR
Johns Hopkins University
Frequently Asked Questions
Who can join the NCT07209176 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Metastatic Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07209176 currently recruiting?
Yes, NCT07209176 is actively recruiting participants. Contact the research team at chm@jhmi.edu for enrollment information.
Where is the NCT07209176 trial being conducted?
This trial is being conducted at Baltimore, United States.
Who is sponsoring the NCT07209176 clinical trial?
NCT07209176 is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The principal investigator is Catherine Marshall, MD at Johns Hopkins University. The trial plans to enroll 256 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.